Last updated: April 3, 2024
Sponsor: The University of Texas Health Science Center, Houston
Overall Status: Active - Recruiting
Phase
1
Condition
Neurologic Disorders
Treatment
Nicotinamide riboside (NR)
Clinical Study ID
NCT06280482
HSC-MS-23-0332
Ages 5-18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- bodyweight ≥ 12 kg
- native (not surgically replaced) ascending aorta
- diagnosed with SMDS with confirmed ACTA2 mutation disrupting arginine 179
- females with negative urine pregnancy test
- must agree to use acceptable method of contraception, including abstinence, a barriermethod (diaphragm or condom), Depo-Provera, or an oral contraceptive, for the durationof the study
Exclusion
Exclusion Criteria:
- Individuals who have undergone surgery to replace aneurysmal or dissected ascendingand root aortic tissue with a graft.
- Additional medical conditions that impair the patient's ability to participate in thestudy.
- Known allergy or sensitivity to niacin or nicotinamide riboside.
- Prior consumption of niacin or nicotinamide riboside supplement within the prior eightweeks.
- Failure to provide informed consent.
- Inability to tolerate PET/CT imaging and echocardiography without sedation.
- Concurrent participation in another intervention trial.
Study Design
Total Participants: 5
Treatment Group(s): 1
Primary Treatment: Nicotinamide riboside (NR)
Phase: 1
Study Start date:
March 06, 2024
Estimated Completion Date:
July 25, 2025
Connect with a study center
The University of Texas Health Science Center at Houston
Houston, Texas 77030
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.